source
- Merck KGaA to acquire Silence Therapeutics for $1.3 billion, expanding siRNA portfolioMerck KGaA, the German science and technology conglomerate, announced an agreement to purchase UK‑based Silence Therapeutics. The deal is valued at about $1.3 billion and gives Merck access to Sil…
- Disc Medicine's rare sun-sensitivity drug meets all endpoints in Phase 3 trialDisc Medicine announced that its experimental therapy for a rare condition that makes sun exposure painful has completed a Phase 3 study. The trial reported success on every primary and secondary…